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A B S T R A C T
Background
Gastro-oesophageal reflux (GOR) is common and usually self-limiting in infants. Cisapride, a pro-kinetic agent, was commonly
prescribed until reports of possible serious adverse events were associated with its use.
Objectives
To determine the effectiveness of cisapride versus placebo or non-surgical treatments for symptoms of GOR.
Search methods
We searched theCochraneUpperGastrointestinal andPancreaticDiseasesGroupSpecialisedRegister andCentral Register ofControlled
Trials (CENTRAL), MEDLINE and EMBASE, reference lists of relevant review articles and searched in the Science Citation Index
for all the trials identified. All searches were updated in February 2009.
Selection criteria
Randomised controlled trials comparing oral cisapride therapy with placebo or other non-surgical treatments for children diagnosed
with GOR were included. We excluded trials with a majority of participants less than 28 days of age.
Data collection and analysis
Primary outcomeswere a change in symptoms at the endof treatment, presence of adverse events, occurrence of clinical complications and
weight gain. Secondary outcomes included physiological measures of GOR or histological evidence of oesophagitis. We dichotomised
symptoms into ’same or worse’ versus ’improved’ and calculated summary odds ratios (OR). Continuous measures of GOR (for example
reflux index) were summarised as a weighted mean difference. All outcomes were analysed using a random-effects method.
Main results
Ten trials in total met the inclusion criteria. Nine trials compared cisapride with placebo or no treatment, of which eight (262
participants) reported data on symptoms of gastro-oesophageal reflux. There was no statistically significant difference between the two
interventions (OR 0.34; 95% CI 0.10 to 1.19) for ’same or worse’ versus ’improved symptoms’ at the end of treatment. There was
significant heterogeneity between the studies, suggesting publication bias. Four studies reported adverse events (mainly diarrhoea); this
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difference was not statistically significant (OR 1.80; 95%CI 0.87 to 3.70). Another trial found no difference in the electrocardiographic
QTc interval after three to eight weeks of treatment. Cisapride significantly reduced the reflux index (weighted mean difference -
6.49; 95% CI -10.13 to -2.85; P = 0.0005). Other measures of oesophageal pH monitoring did not reach significance. One included
study compared cisapride with Gaviscon (with no statistically significant difference). One small study found no evidence of benefit on
frequency of regurgitation or weight gain after treatment with cisapride versus no treatment, carob bean or corn syrup thickeners.
Authors’ conclusions
We found no clear evidence that cisapride reduces symptoms of GOR. Due to reports of fatal cardiac arrhythmias or sudden death,
from July 2000 in the USA and Europe cisapride was restricted to a limited access programme supervised by a paediatric gastrologist.
P L A I N L A N G U A G E S U M M A R Y
Cisapride treatment for gastro-oesophageal reflux in young children
Gastro-oesophageal reflux is the movement of stomach contents back into the oesophagus. A ring of smooth muscle (sphincter) at the
lower end of the oesophagus near the stomach usually prevents this regurgitation. Relaxation of the sphincter, ineffective clearance of
food from the oesophagus into the stomach, and delayed emptying of the stomach can all contribute to reflux. The peak incidence of
reflux is generally at around four months of age and resolves by one to two years. Parents may seek medical help for the reflux if they
are anxious or find the symptoms of regurgitation, crying, irritability, vomiting and, gagging difficult to tolerate. Some young children
experience associated respiratory problems of chronic cough, wheezing, hoarseness, recurring bronchitis, pneumonia, apnoea or breath
holding; and back-arching, refusal to feed and sleep disturbance. Inflammation of the oesophagus may be evident with endoscopy or
the child may fail to thrive and surgery may be required. Scintigraphy or sonography are used to monitor oesophageal motility.
Attention to the child’s position (by avoiding lying flat or a slumped seated position) and diet (thickened feeds, frequent small meals,
non-prescription stabilisers such as Gaviscon) may be effective in reducing reflux. Medications include prokinetic drugs given before a
meal to stimulate gut motility and acid-secretion inhibitors. Cisapride is a prokinetic drug used to improve symptoms and avoid serious
complications of reflux. From this systematic review, we found no clear evidence of reduced symptoms of reflux with cisapride compared
to placebo or no treatment. The parent or guardian of the child or the treating physician assessed the symptoms (regurgitation, crying,
irritability, vomiting, gagging) at the end of treatment. Nine trials compared cisapride with placebo or no treatment, of which eight
(262 participants) reported data on symptoms of gastro-oesophageal reflux in children aged between five days and five years. They were
followed up for two weeks to eight weeks.
Investigations of reflux can include oesophageal pH monitoring for 18 to 24 hours to determine the number of episodes of pH < 4,
duration of the longest episode of pH < 4 and the presence of sleep reflux. These pH measurements poorly correlate with symptoms
and responses of a child to treatment.
Cisapride significantly reduced the percentage of time the pH < 4 (reflux index) but not other measures of oesophageal pH monitoring
Fatal cardiac arrhythmia or sudden death have been associated with cisapride use in children and it is only used within restricted
programmes under specialist supervision. One multicentre study of 134 children found no electrocardiographic QTc interval changes
with cisapride.
B A C K G R O U N D
Description of the condition
Gastro-oesophageal reflux (GOR), or the passage of gastric con-
tents into the oesophagus, has a multifactorial pathophysiology.
Regurgitation of stomach contents into the oesophagus is normally
prevented by the action of the lower oesophageal sphincter (LOS).
Two different mechanisms contribute to LOS tone. These are the
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skeletal muscle of the diaphragm which surrounds the oesopha-
gus as it passes through the diaphragm and the smooth muscle at
the gastro-oesophageal junction. Low basal oesophageal sphinc-
ter pressure and transient relaxation of the LOS, oesophageal dys-
motility resulting in impaired clearance, and delayed emptying of
the stomach and duodenum can all contribute to GOR.
In most infants with GOR the outcome is benign. The determin-
ing factor in seeking medical assistance may be parental anxiety
or intolerance of symptoms rather than the presence of significant
complications. In a small minority, GOR is associated with signifi-
cant problems such as respiratory sequelae (chronic cough, wheez-
ing, apnoea, hoarseness, stridor, recurrent bronchitis, pneumo-
nia), neuro-behavioural manifestations (back-arching, feeding re-
fusal, rumination, non-specific irritability, sleep disturbance), oe-
sophagitis, oesophageal strictures, and failure to thrive. The term
gastro-oesophageal reflux disease (GORD) describes the associa-
tion of definite pathology, in most cases oesophagitis, with reflux.
Infantile gastro-oesophageal reflux has a peak incidence around
four months and resolves spontaneously by one to two years of age
in most patients (Nelson 1997; Rudolph 1996). A much smaller
number of children have symptoms of GOR later in childhood;
only some of these children will have had GOR in infancy. Less
than 50% of children who develop reflux after the age of three
years have spontaneous resolution of symptoms (Treem 1991). A
substantial proportion of these children will have other problems
including neurological or chronic respiratory disease.
A diagnosis of GOR is usually made on clinical grounds. Treat-
ment for GOR, when this is deemed necessary, can be started
before performing expensive and often unnecessary investigations
(the Working Group of the European Society of Paediatric Gas-
tro-Enterology and Nutrition (ESPGAN) onGastro-Oesophageal
Reflux, in Vandenplas 1993). Though not always essential for di-
agnosis, there are a number of investigations available to assess the
cause andquantity of the reflux and todetect the presence of reflux-
related complications. Investigations are extended (18 to 24 hour)
oesophageal pH monitoring, upper gastro-intestinal endoscopy,
oesophageal manometry, scintigraphy or sonography. These have
low sensitivities and specificities and do not allow correlation of
the reflux episodes with the patient’s symptoms. Moreover, these
investigations are generally poor predictors of how children will
respond to treatment (Cucchiara 1996). A few variables, for ex-
ample sleep reflux, acid clearing time, percentage time pH < 4
and oesophageal motility parameters, may predict which children
are likely to have continuing problems despite medical treatment
(Colson 1990; Cucchiara 1996; Varty 1993).
Description of the intervention
There are fourmain types of therapy in infants withGOR: surgery,
drugs, dietary measures (thickened feeds, frequent small meals)
and positioning (avoidance of slumped seated or supine postures).
Surgical treatment is usually reserved for complicated cases, while
most cases are treatedwith some combination of the other options.
Pharmacological therapies include acid-secretion inhibitors (for
example cimetidine, ranitidine, omeprazole, lansoprazole) with
or without prokinetic agents (for example cisapride, bethanechol,
metoclopramide) when oesophagitis is present.
How the intervention might work
Cisapride is administered orally 15 to 30 minutes before a meal
to ensure maximum plasma levels of the medication immediately
after food intake. It is a gastrointestinal prokinetic agent which
stimulates lower oesophageal, gastric, small intestinal and colonic
motility, probably acting by enhancing the release of acetylcholine
at the level of the myenteric plexus in the gut wall.
Why it is important to do this review
Although cisapride has never been licensed for children under 12
years of age, it has been prescribed to over 36 million children
worldwide (Vandenplas 1999) including 19% of preterm new-
borns inCanadian neonatal units (Ward 1999). In 1999, a consen-
sus statement by the European Society of PaediatricGastroenterol-
ogy, Hepatology and Nutrition (Vandenplas 1999) recommended
cisapride as the drug of first choice. stating that “the potential
benefits far outweigh the potential risks and provide strong justi-
fication for its continued use”. Since 1993 there have been 175 re-
ports worldwide of fatal cardiac arrhythmia or sudden death asso-
ciated with cisapride use, including at least two deaths in children,
and 261 reports of non-fatal but serious ventricular arrhythmias
(Klausner 1998). These adverse events led to the withdrawal of cis-
apride from the UK and USAmarkets in July 2000 (Breckenridge
2000;Henney 2000). To date, the effectiveness of cisapride for the
treatment of reflux in children has not been systematically evalu-
ated. As cisapride continues to be used, albeit within restricted pro-
grammes in the USA (Henney 2000) and Europe (EMEA 2002),
information on its effectiveness is required to enable clinicians and
policy makers to decide whether the low risk of serious adverse
events is outweighed by the benefits of treatment.
O B J E C T I V E S
The objective of this review was to compare the effectiveness of
cisapride in reducing the symptoms of gastro-oesophageal reflux
with:
1. placebo or no treatment;
2. other medical treatments;
3. dietary interventions;
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4. positioning;
5. any combination of the other treatments.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Searches were carried out for randomised controlled trials com-
paring oral cisapride therapy with placebo or other non-surgical
treatments (other prokinetic drugs, with or without acid-secretion
inhibitors, dietary measures, positioning) in children with gastro-
oesophageal reflux. Searches for unpublished data are ongoing.
Types of participants
Children (aged less than 18 years) with a diagnosis of gastro-oe-
sophageal reflux, however defined. We excluded trials in which
the majority of participants were aged less than 28 days. This is
because cisapride is prescribed to neonates for feed intolerance,
which is a different clinical entity from gastro-oesophageal reflux
that may be due to different physiological mechanisms. It may re-
spond differently to cisapride than does GORD in older children
(Enriquez 1998).
Types of interventions
1. Cisapride versus no treatment or placebo
2. Cisapride versus other medical therapies (bethanechol,
metoclopramide, cimetidine, ranitidine, omeprazole,
lansoprazole, Gaviscon)
3. Cisapride versus dietary interventions (small meals,
thickened infant feeds)
4. Cisapride versus positioning (avoidance of slumped seated
or supine postures)
5. Cisapride versus any combination of other non-surgical
therapies
Because of the restriction of surgical treatment to complicated
cases of GOR, we did not expect to find randomised controlled
trials in this area and they were not sought.
We looked for studies in which cisapride was administered orally
for a minimum of one week.
Types of outcome measures
Cisapride treatment usually precedes physiological investigations
for GOR and primarily aims to improve symptoms and avoid
serious complications of GOR.
Primary outcomes
• Symptoms, or changes in symptoms, of gastro-oesophageal
reflux (regurgitation, crying, irritability, vomiting, gagging)
assessed subjectively by the parent or guardian of the child or by
the treating physician, or both.
• Presence of any of the following adverse events: abdominal
pain, borborygmi, diarrhoea, headaches, hypersensitivity,
convulsions, extrapyramidal effects, increased urinary frequency,
liver function abnormalities, increased QTc interval on the
electrocardiogram (ECG).
• Occurrence of any clinical complications of GOR, e.g.
respiratory symptoms.
• Weight gain.
Secondary outcomes
• Episodes of reflux measured by extended duration
oesophageal pH monitoring: percentage of time during which
pH < 4 (’reflux index’), number of episodes of pH < 4, number
of episodes of pH < 4 lasting > 5 minutes, duration of longest
episode of pH < 4.
• Lower oesophageal sphincter (LOS) pressure measured by
oesophageal manometry.
• Histological evidence of oesophagitis on biopsy.
Included studies had to report at least one of the primary outcomes.
Search methods for identification of studies
See: Cochrane UpperGastrointestinal and Pancreatic Diseases Re-
view Group search strategy
For the first version of this review, searches were conducted of
the Cochrane Central Trials Register (CCTR) and the specialised
trials register of the Cochrane Upper Gastrointestinal and Pan-
creatic Diseases Group (see Review Group details for more infor-
mation) using terms related to gastro-oesophageal reflux and cis-
apride. In addition, the review authors searched the MEDLINE
and EMBASE electronic databases. The search strategy included
appropriate MeSH terms and text terms including: cisapride, gas-
tro-oesophageal reflux, idiopathic gastro-oesophageal reflux, un-
complicated gastro-oesophageal reflux, gastro-oesophageal reflux
disease, infantile reflux, regurgitation, excessive regurgitation, and
with appropriate truncations and misspellings. These were com-
bined with the use of the most sensitive Cochrane trials filters.
Reference lists of relevant review articles and identified trials were
scrutinised and forward citation searches were performed in the
Science Citation Index on all trials identified. The drug manufac-
turers were contacted for any unpublished trials.
Searches were updated on The Cochrane Library, pre-MEDLINE,
EMBASE (5 April 2002) using the above strategy. An adapted
strategy was used for PubMed. The pharmaceutical company
Janssen was contacted for unpublished trials. The searches were
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re-run in August 2003, May 2004, June 2005 and June 2006 and
no new trials were found.
For the update in 2009, trials were identified by searching the
Cochrane Central Register of ControlledTrials (CENTRAL) (The
Cochrane Library 2008, Issue 4), MEDLINE (2005 to February
2009) andEMBASE (2005 to February 2009).We did not confine
our search to English language publications.
The Cochrane highly sensitive search strategy for identifying ran-
domised trials inMEDLINE, sensitivitymaximising version,Ovid
format (Higgins 2009) was combined with the search terms in
Appendix 1 in order to identify randomised controlled trials in
MEDLINE. The MEDLINE search strategy was adapted for use
in the other databases that were searched.
Data collection and analysis
Selection of studies
Titles and abstracts of all studies identified by the electronic
searches were independently reviewed on screen by two review au-
thors (CA, SM).
Data extraction and management
All potentially eligible studies were retrieved in hard copy andwere
independently reviewed by two researchers (CA, SM in 2002; SM,
RG in 2009) against the inclusion criteria. Disagreements were
resolved by consensus with provision for arbitration by a third
review author, if required (RG or SL). Additional information
was sought for one included trial (Cohen 1999). The reasons for
exclusion of trials are given in the table ’Characteristics of excluded
studies’.
Assessment of risk of bias in included studies
The methodological quality of the included trials was assessed
independently by two review authors (CA, SM in 2002; SM, RG
in 2009) using a checklist developed for this purpose. For each
included trial, information was collected regarding the method
of randomisation, allocation concealment, blinding of outcome
assessment, and the relevant interventions and outcomes. Data
were extracted independently by two review authors (CA, SM in
2002; RG and LCG in 2009) and any discrepancies were discussed
and resolved. Data were then entered into the Review Manager
software by one review author (CA or LCG) and accuracy was
checked by two other authors (SM, RG).
Measures of treatment effect
For dichotomous data, a random effects model meta-analysis was
performed to determine a summary odds ratio (OR). Where con-
tinuous data outcomes were measured in a standard way across
studies (for example reflux index), the pooled weighted mean
difference (WMD) was calculated again using a random effects
model. The denominators for these calculations were all children
for whom outcome data had been reported. Analysis was by in-
tention to treat. Sensitivity analyses involved re-calculation of the
summary OR for trials with good allocation concealment. For the
primary outcome of ’same or worse’ symptoms we analysed funnel
plot asymmetry, and hence the likelihood of bias, using the regres-
sion method as described by Egger et al (Egger 1997). Evidence
of heterogeneity was sought using a standard Chi2 statistic.
Assessment of heterogeneity
To assess heterogeneity, we conducted subgroup analyses accord-
ing to study quality and produced a funnel plot for the primary
outcome ’same or worse symptoms versus improvement’ (Figure
1).
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Figure 1. Funnel plot of comparison: 1 Main analysis for cisapride versus no treatment, outcome: 1.1
’Worse, same or slight improvement’ versus ’moderate or excellent improvement’.
Data synthesis
We preferentially included symptoms assessed by parents as the
parents are likely to have greater contact with their child and there-
fore have a more accurate view of the change in symptoms. How-
ever, we included physician measures of symptoms where parental
assessments were not available, as we considered that they were
assessing the same entity.
Studies reported symptoms or changes in symptoms at the end
of the treatment period in a variety of ways. An a priori decision
was made to dichotomise data as ’same or worse’ versus ’improve-
ment’. In a sensitivity analysis we examined the effect of redefining
the outcomes as ’any symptoms’ versus ’no symptoms’. Decisions
about how best to dichotomise the data were reached by two re-
view authors (RG, SL) without knowledge of the results. Changes
in oesophageal pH measurements at the end of treatment were
considered to be a secondary outcome as pH measurements are
not reliable (Hampton 1990); they correlate poorly with symp-
toms and the response to treatment (Cucchiara 1996). We were
able to analyse results for the reflux index (percentage of 24 hrs
with oesophageal pH < 4) as this was themost commonly reported
measure.
Subgroup analysis and investigation of heterogeneity
Planned subgroup analyseswere: in childrenunder andover the age
of one year, uncomplicated and complicated gastro-oesophageal
reflux, for those with neurological impairment, and in trials where
the assessment of outcomes was blinded versus those in which as-
sessment was non-blinded. These were not conducted as appro-
priate trials were not identified.
R E S U L T S
Description of studies
Results of the search
Ten trials met the inclusion criteria (see Characteristics of included
studies). Nine of these compared the effects of cisapride with
placebo or no treatment (Cohen 1999; Cucchiara 1987; Escobar
Castro 1994; Levy 2001; Moya 1999; Scott 1997; Van Eygen
1989(a); Van Eygen 1989(b); Vandenplas 1991). Limited results
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were reported from an unpublished study of symptomatic children
over two months old with biopsy-proven oesophagitis that com-
pared cisapride with cimetidine and placebo (Orenstein 2000).
The results were published only in abstract form but the lead in-
vestigator provided a summary in a personal communication. Due
to the limited nature of the data provided (see Characteristics of
included studies), this study could not be included in our analysis.
Included studies
In two studies (Scott 1997;Vandenplas 1991) positioning or thick-
ened feeds, or both, were given in both the experimental and con-
trol arms. One paper (Van Eygen 1989(a),(b)) presented data from
three trials. Two of these were on different patient populations and
met our inclusion criteria; they were reviewed separately and are
identified accordingly. In one trial (Greally 1992) cisapride was
compared with Gaviscon with or without Carobel. The most re-
cently identified study was a four-arm trial with six to eight partic-
ipants in each arm. This study compared cisapride with no treat-
ment and with thickened feeds using carob bean or corn syrup
(Moya 1999). The study reported on two of our primary out-
comes: change in the number of regurgitations and weight gain.
Most studies reported outcomes based on a change in symp-
toms following the intervention. The exceptions were: the Escobar
Castro 1994 study which reported symptoms at the end of the
treatment period; and the study by Cucchiara 1987 in which im-
provement in symptoms alone could not be separated from im-
provement in the pH probe results and histopathological changes.
Both these studies were included and their contribution to the
overall results was explored in a sensitivity analysis. Moya 1999
did not report overall symptom improvement for each participant
but analysed mean number of regurgitations during the treatment
period as well as mean daily weight gain.
The study by Levy 2001 only reported data on the QTc interval
of the ECG. These data were from a seven-centre double-blind,
placebo-controlled study of 134 children on the safety and effi-
cacy of cisapride. It was conducted from 1991 to 1994 with the
support of Janssen Pharmaceutical Inc. Levy et al stated that “be-
cause efficacy results did not reach statistical significance (possibly
because inclusion criteria were too broadly defined), they were not
published”. The response to a request to Janssen-Cilag Ltd UK for
unpublished data was that they were not aware of any unpublished
data. No further information has been provided.
The children included in the trials were aged between five days
and five years. They had a diagnosis of GOR, defined by clinical
symptoms alone or with additional oesophageal pH monitoring.
Children were generally excluded from the trials if they: required
concomitant therapy with drugs interfering with assessment of the
study drug; had reflux caused by known anatomic abnormalities;
had underlying disease; had an infection of the gastrointestinal
(GI) tract or other organ system; or had neurologic, metabolic, or
renal disorders (see table ’Characteristics of included studies’).
The dosage of cisapride that was used was 0.8 mg/kg/day, with
three exceptions: in one study (Cucchiara 1987) 0.9 mg/kg/day
was used, in another (Van Eygen 1989(a)) 0.45 mg/kg/day, and in
another study (Levy 2001) 0.6mg/kg/day.One study (Moya1999)
stated that the usual dosagewas given in three divideddoses but did
not specify the amount. The duration of follow up varied slightly
over all studies: four studies followed participants up for twoweeks
(Cohen 1999; Cucchiara 1987; Moya 1999; Vandenplas 1991);
four studies up to four weeks (Escobar Castro 1994; Greally 1992;
Van Eygen 1989(a); Van Eygen 1989(b)); one up to six weeks
(Scott 1997), and another for eight weeks (Greally 1992). In five
of the nine included trials that compared the effects of cisapride
with placebo or no treatment cisapride had been supplied by the
manufacturing company (Cohen 1999; Greally 1992; Scott 1997;
Van Eygen 1989(a); Van Eygen 1989(b)).
Excluded studies
Eight studies identified by the search strategy were excluded: in
two (Cucchiara 1990; Saye 1987) cisapride had been given for
less than 24 hours; in three (Barnett 2001; Pezzati 2001; McClure
1999) cisapride was administered to preterm infants with feed
intolerance; in two studies cisapride was administered prophy-
lactically to preterm infants for feed intolerance (Enriquez 1998;
Reddy 2000); and two studies did not report any of the outcomes
required for inclusion in the review (Heine 1996;McClure 1999).
Please see the ’Characteristics of excluded studies’ table for further
details.
Risk of bias in included studies
Two trials reported adequate allocation concealment (Cohen
1999; Scott 1997). In the remaining eight trials the method used
for allocation concealment was unclear (Figure 2). In one study
(Greally 1992) a double-blind design was not feasible due to
the different mode of preparation and time of administration
of cisapride and Gaviscon with or without Carobel. Eight trials
stated that they were double blind (Cohen 1999; Cucchiara 1987;
Escobar Castro 1994; Greally 1992; Levy 2001; Scott 1997; Van
Eygen 1989(a); Vandenplas 1991; Van Eygen 1989(b)). Details of
blinding of participants were often given but no trial gave explicit
information on the blinding of key study personnel for the dura-
tion of the study (Figure 2). The most recent study to be included
in this review (Moya 1999) was not blinded and provided no in-
formation on how randomisation was performed or how alloca-
tion was concealed.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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In one study all of the randomised infants completed the study
(Greally 1992). Losses to follow up in the other studies varied from
as little as one and three (Cucchiara 1987; Escobar Castro 1994),
respectively, to as much as 30% of the randomised population in
three studies (Cohen 1999; Levy 2001; Vandenplas 1991). In the
study byCucchiara 1987 the total number of participants included
was reported, as was the number of participants for each group
who completed the trial; the number randomised to the treatment
and control arms was not. For this study we made the assumption
that randomisation had produced equal numbers in each group.
Moya 1999 provided no information on losses to follow up but
we assumed that all participants completed the study.
Effects of interventions
Cisapride versus placebo or no treatment
Eight trials including 262 participants compared symptoms of
GOR after treatment with cisapride or no treatment. Analysis of
symptoms was based on parental evaluation in five trials (Cohen
1999; Escobar Castro 1994; Moya 1999; Scott 1997; Vandenplas
1991) and physician assessment in the remaining three trials (
Cucchiara 1987; Van Eygen 1989(a); Van Eygen 1989(b)). The
pooled OR (random-effects model) for cisapride versus placebo
for ’same or worse’ symptoms versus ’improvement’ based on seven
trials (excluding Moya 1999) was 0.34 (95% CI 0.10 to 1.19)
(Analysis 1.1). The trial by Moya 1999 showed no significant
difference in the number of regurgitations per day between groups
treated with cisapride or no treatment, at 15 days follow up (
Analysis 1.2).
The OR for cisapride versus placebo for ’same or worse’ versus
’improvement’ in symptoms after exclusionof the study byEscobar
Castro 1994 (OR 0.59; 95% CI 0.22 to 1.59) or Cucchiara 1987
(OR 0.41; 95% CI 0.11 to 1.54) did not change appreciably (data
not shown). Analysis of the effects of cisapride after re-defining
outcomes as ’any symptoms’ versus ’no symptoms’ was restricted
to five trials (a total of 156 participants) (Cucchiara 1987; Escobar
Castro 1994; Scott 1997; Van Eygen 1989(a); Van Eygen 1989(b);
Vandenplas 1991). The pooled OR (random-effects model) for
cisapride versus no treatment was 0.19 (95% CI 0.08 to 0.44)
(Analysis 4.3).
The analysis of ’same or worse’ versus ’improvement’ in symptoms
showed significant heterogeneity (Chi2 =24.23; df = 6; P =0.0005;
I2 = 75%) (Analysis 1.1). The reasons for the heterogeneity were
not obvious from examination of the included trials, which were
conducted in clinically similar populations and reported similar
baseline event rates. The funnel plot was asymmetrical, suggesting
an absence of small studies showing small or nobenefit of cisapride.
The intercept was -5.07 (95% CI -7.18 to -2.95). This result is
consistent with publication bias favouring studies that showed a
positive effect of cisapride. The results regarding the benefits of
cisapride should therefore be interpreted with caution.
Adverse events
Adverse events (principally diarrhoea) were reported in four trials
(a total of 190 participants). There were fewer adverse events in the
non-treatment group than in the cisapride group but the difference
was not statistically significant (OR for cisapride versus placebo
1.86; 95% CI 0.88 to 3.93) (Analysis 1.5). One trial (Levy 2001)
reported data on theQTc interval following three to eight weeks of
either cisapride or placebo. No statistically significant differences
were found between the two groups in either total QTc interval
duration or change in QTc interval compared to baseline. Mean
QTc was 408 ± 21 ms in the cisapride group and 399 ± 21 ms in
the placebo group; the change in QTc was 1.7 ± 18 ms and 2.4 ±
20 ms, respectively.
A primary outcome for our study was weight gain following the
intervention but only two studies reported this outcome (Cohen
1999; Moya 1999). For the study by Cohen 1999 the mean dif-
ference in weight gain at the end of the two week trial was based
on data provided by the authors. In the study by Cohen 1999 the
difference between the two groups was not statistically significant
(0.9 kg; 95% CI -0.38 to 2.18) (data not shown). Moya 1999
reported no difference in mean daily weight gain between infants
given cisapride and those with no treatment (Analysis 1.3).
Use of cisapride was associated with a reduction in the reflux in-
dex, as measured by oesophageal pH monitoring, in five studies.
The weighted mean difference for cisapride versus no treatment
was -6.49 (95% CI -10.13 to -2.85) (Analysis 1.4). Several other
physiological measured were reported. The differences between
the cisapride and the placebo groups were not statistically signifi-
cant for: number of episodes of pH < 4 in 24 hours (data available
from two studies), number of reflux episodes lasting more than 5
min (data from three studies), or number over the course of a day
(one study).
For this review we also looked for histological evidence of oe-
sophagitis at biopsy. Three trials reported data. In Cohen 1999
only six of 68 participants underwent endoscopy and there was
no difference in the presence of ’mild histologic oesophagitis’ be-
tween the cisapride and the placebo group (2/4 versus 1/2). In
Cucchiara 1987 the degree of oesophagitis was histologically de-
fined as ’mild’, ’moderate’ or ’severe’ and transformed into a score.
Cisapride was more effective than placebo but only three of the 17
participants included in the study had severe oesophagitis at the
beginning. In Scott 1997 the biopsy was repeated at the end of the
trial only if oesophagitis had been present at baseline. The differ-
ence in abnormal findings between the cisapride and the placebo
groups (7/11 versus 5/9) was not statistically significant.
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Cisapride versus other medical interventions
(Gaviscon)
One study comparing cisapride with Gaviscon (or Gaviscon and
carob bean thickener in 21 of the 24 cases) was identified (Greally
1992). The ’same or worse symptoms’ were slightly more com-
mon in the cisapride group than in the Gaviscon group but this
difference was not significant (OR 3.26; 95% CI 0.93 to 11.38)
(Analysis 2.1). The outcomes in this study were based on evalua-
tions by parents who were not blind to the intervention.
Cisapride versus dietary interventions
One study compared cisapride with two dietary interventions,
carob bean thickener and corn syrup (Moya 1999). As the au-
thors did not provide details of overall symptom improvement for
each patient, we were not able to calculate an OR for ’same or
worse’ versus ’improvement’ in symptoms (Analysis 3.1). There
was no significant difference in the number of regurgitations per
day at the end of 15 days follow up between infants treated with
cisapride, carob bean or corn syrup (Analysis 3.2; Analysis 3.4).
There was a greater mean daily weight gain in infants given corn
syrup compared with cisapride (MD -3.70; 95% CI -10.46 to
3.06) (Analysis 3.5) but no significant difference between carob
bean and cisapride (Analysis 3.3). No adverse events were reported
when comparing cisapride against the other interventions.
D I S C U S S I O N
Summary of main results
We found no clear evidence for a significant effect of cisapride
compared with placebo on symptoms of GOR in children. How-
ever, the midpoint estimate of the summary OR was 0.34. This
result is likely to be an overestimate of the benefits of cisapride.
Overall completeness and applicability of
evidence
The analysis of funnel plot asymmetry showed that the intercept
from the regression analysis was -5.07 (Figure 1). In an analysis of
75 meta-analyses published in The Cochrane Library and in four
leading journals, Egger 1997 reported intercepts varying from -
3.5 to +3.5. In comparison, our result shows extreme asymmetry
reflecting an inverse association between study precision and an
apparent beneficial effect of cisapride. While this relationship may
reflect real differences between large and smaller trials, it may be
explained by publication bias favouring submission or publica-
tion of small positive studies rather than small negative studies.
This possibility is supported by the report of a multicentre trial
of 96 children randomised to either cisapride or placebo (with or
without cimetidine) which was not published “because efficacy
results did not reach statistical significance (possibly because in-
clusion criteria were too broadly defined)” (Levy 2001). The six
smallest studies in this review had unclear allocation concealment,
which has been reported to be associated with an overestimate of
treatment effect (Schulz 1995). If the analysis was restricted to the
two trials with good allocation concealment the summary ORwas
1.94 (95%CI 0.87 to 4.31) (data not shown).
Quality of the evidence
There was substantial heterogeneity of results between trials. The
source of this heterogeneity is unclear as there was no obvious
clinical heterogeneity (age, method of GOR diagnosis, dose and
duration of interventions were broadly similar).
We found a statistically significant reduction in the reflux index
with cisapride compared to no treatment. The reflux index is gen-
erally taken to be the percentage of time with pH < 4 over 24
hours of pH monitoring; the reduction suggested by this analysis
was equivalent to 1.5 hours (with 95%CI of 40 minutes to almost
2.5 hours). This finding however has to be seen in the context of a
lack of correlation between the reflux index and clinical symptoms
and the evidence of publication bias.
A small study was found which compared the use of cisapride with
Gaviscon or a combination of Gaviscon and carob bean thickener
(Greally 1992), the results did not reach conventional levels of sta-
tistical significance. A further study showed no difference between
cisapride and carob bean thickener or corn syrup for mean daily
regurgitation frequency or daily weight gain (Moya 1999).
This review did not find a statistically significant difference in ad-
verse events between cisapride and no treatment. However, serious
adverse events are rare and are unlikely to be detected by small
trials. Recent reports from surveillance studies of death and life
threatening events potentially related to cisapride, together with
the uncertain benefits of cisapride, have led to the decision to stop
marketing cisapride in the United States (Henney 2000).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our findings of a lack of evidence for a beneficial effect of cis-
apride contradict previous widely held opinions to the contrary
(Shulman 2000; Vandenplas 1999). This review found no statisti-
cally significant effect of cisapride on symptoms ofGOR, although
the results were consistent with a substantial reduction, no effect,
or even an increase in symptoms associated with cisapride treat-
ment compared with placebo. In this review there was evidence
of substantial funnel plot asymmetry which may be explained by
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publication bias. There was also statistical heterogeneity between
the trials that may be related to variation in study quality. For these
reasons, the results are uncertain and should be interpreted with
caution. Finally, this review has highlighted the paucity of ran-
domised controlled trial information for such a widely prescribed
drug. However, due to the potential for serious adverse events,
large randomised trials of cisapride that have long-term follow up
are unlikely to be conducted.
Implications for research
The literature search did not find sufficient trials to fulfil all the
objectives of this review. Due to the restricted use of cisapride since
July 2000, a larger study to determine the effectiveness of cisapride
for children with GOR is no longer possible.
A C K N OW L E D G E M E N T S
We thank Professor Geoffrey P Davidson for providing additional
information for one study trial; Dr Billy Bourke, Professor B
Drumm andDr Jaqui Dalby-Payne for their comments on the first
draft of the original review; Susan Orenstein for her comments on
a subsequent version and for a personal communication about the
results of her unpublished study; and Melissa Harden for assist-
ing in the search for unpublished trials from the pharmaceutical
company Janssen.
R E F E R E N C E S
References to studies included in this review
Cohen 1999 {published and unpublished data}
Cohen RC, O’Loughlin EV, Davidson GP, Moore DJ,
Lawrence DM. Cisapride in the control of symptoms in
infants with gastroesophageal reflux. A randomized, double-
blind, placebo-controlled trial. Journal of Pediatrics 1999;
134:287–92.
Davidson GP. Personal communication [Clarification of
trial characteristics and additional data]. Meeting 14.09.99.
Cucchiara 1987 {published data only}
Cucchiara S, Staiano A, Capozzi C, Di Lorenzo C, Boccieri
A, Auricchio S. Cisapride for gastro-oesophageal reflux and
peptic oesophagitis. Archives of Disease in Childhood 1987;
62:454–7.
Escobar Castro 1994 {published data only}
Escobar Castro H, Bettas Ferrero G, Suarez Cortina L,
Camarero Salces C, Lima M. Efficacy of cisapride in the
treatment of gastroesophageal reflux (GER) in children.
Evaluation of a double blind study [Efectividad del
Cisapride en el tratamiento del reflujo gastroesofagico
(R.G.E.) en ninos. Valoracion de un estudio a doble ciego].
Anales Espanoles de Pediatria 1994;40(1):5–8.
Greally 1992 {published data only}
Greally P, Hampton FJ, MacFadyen UM, Simpson H.
Gaviscon and Carobel compared with cisapride in gastro-
oesophageal reflux. Archives of Disease in Childhood 1992;
67:618–21.
Levy 2001 {published data only}
Levy J, Hayes C, Kern J, Harris J, Flores A, Hyams J, et
al. Does cisapride influence cardiac rhythm? Results of a
United States multicenter, double-blind, placebo-controlled
pediatric study. Journal of Pediatric Gastroenterology and
Nutrition 2001;32:458–63.
Moya 1999 {published data only}
Moya M, Juste M, Cortes E, Auxina A, Ortiz L. Clinical
evaluation of the different therapeutic possibilities in the
treatment of infant regurgitation. [Valoracion clinica de
las distintas posibilidades terapeuticas en el manejo de las
regurgitaciones del lactante]. Revista Espanola de Pediatria
1999;55(3):219–23.
Orenstein 2000 {published and unpublished data}
Orenstein SR. Personal communication [Additional data
and details regarding completion of the study]. Email
11.06.09.
Orenstein SR, Shalaby TM, Frankel EA, Kelsey SF.
Cisapride, cimetidine, both or neither for infantile
esophagitis: symptomatic and histologic results of 2-months
randomized, double-blind, placebo-controlled therapy in
100 babies. Gastroenterology 2000;118(4):A20.
Orenstein SR, Shalaby TM, Kelsey SF, Frankel E.
Natural history of infant reflux esophagitis: symptoms
and morphometric histology during one year without
pharmacotherapy. American Journal of Gastroenterology
2006;101(3):628.
Orenstein SR, Shalaby TM, Kelsey SF, Frankel EA.
Cimetidine, cisapride, both or neither for infant esophagitis:
symptomatic response to 6m randomized, double blind,
placebo-controlled therapy in 100 babies. Gastroenterology
2004;126 Suppl 2(4):A508.
Orenstein SR, Shalaby TM, Kelsey SF, Frankel EA.
Cimetidine, cisapride, both or neither for infantile
esophagitis: symptomatic response to 4m randomized,
double-blind, placebo-controlled therapy in 100 babies
[Abstracts: Poster session abstracts]. Journal of Pediatric
Gastroenterology and Nutrition 2004;39 Suppl 1:P0791.
Scott 1997 {published data only}
Scott RB, Ferreira C, Smith L, Jones AB, Machida H,
Lohoues MJ, et al. Cisapride in pediatric gastroesophageal
reflux. Journal of Pediatric Gastroenterology and Nutrition
1997;25:499–506.
Van Eygen 1989(a) {published data only}
Van Eygen M, Van Ravensteyn H. Effect of cisapride on
excessive regurgitation in infants. Clinical Therapeutics
11Cisapride treatment for gastro-oesophageal reflux in children (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1989;11(5):669–77.
Van Eygen 1989(b) {published data only}
Van Eygen M, Van Ravensteyn H. Effect of cisapride on
excessive regurgitation in infants. Clinical Therapeutics
1989;11(5):669–77.
Vandenplas 1991 {published data only}
Vandenplas Y, De Roy C, Sacre L. Cisapride decreases
prolonged episodes of reflux in infants. Journal of Pediatric
Gastroenterology and Nutrition 1991;12:44–7.
References to studies excluded from this review
Barnett 2001 {published data only}
Barnett CP, Omari T, Davidson GP, Goodchild L, Lontis
R, Dent J, et al. Effect of cisapride on gastric emptying
in premature infants with feed intolerance. Journal of
Paediatrics and Child Health 2001;37:559–63.
Cucchiara 1990 {published data only}
Cucchiara S, Staiano A, Boccieri A, De Stefano M, Capozzi
C, Manzi G, et al. Effects of cisapride on parameters of
oesophageal motility and on the prolonged intraoesophageal
pH test in infants with gastro-oesophageal reflux disease.
Gut 1990;31:21–5.
Enriquez 1998 {published data only}
Enriquez A, Bolisetty S, Patole S, Garvey PA, Campbell PJ.
Randomised controlled trial of cisapride in feed intolerance
in preterm infants. Archives of Disease in Childhood. Fetal
and Neonatal Edition 1998;79:F110–3.
Heine 1996 {published data only}
Heine RG, Catto-Smith AG, Reddihough DS. Effect of
antireflux medication on salivary drooling in children with
cerebral palsy. Developmental Medicine and Child Neurology
1996;38:1030–6.
McClure 1999 {published data only}
McClure RJ, Kristensen JH, Grauaug A. Randomised
controlled trial of cisapride in preterm infants. Archives of
Disease in Childhood. Fetal and Neonatal Edition 1999;80:
F174–7.
Pezzati 2001 {published data only}
Pezzati M, Dani C, Biadaioli R, Gambi B, Lachina L,
Rubaltelli FF. Randomised controlled trial of the effect of
cisapride on the pyloric muscle in preterm infants. European
Journal of Pediatrics 2001;160:572–5.
Reddy 2000 {published data only}
Reddy PS, Deorari AK, Bal CS, Paul VK, Singh M. A
double-blind placebo-controlled study on prophylactic use
of cisapride on feed intolerance and gastric emptying in
preterm neonates. Indian Pediatrics 2000;37:837–44.
Saye 1987 {published data only}
Saye ZN, Forget P, Geubelle F. Effect of Cisapride
on gastroesophageal reflux in children with chronic
bronchopulmonary disease: A double-blind cross-over pH-
monitoring study. Pediatric Pulmonology 1987;3:8–12.
Additional references
Breckenridge 2000
Breckenridge A. Suspension of cisapride (Prepulsid) licences:
Product withdrawal. Committee on Safety of Medicines,
London 2000.
Colson 1990
Colson DJ, Campbell CA, Wright VA, Watson BW.
Predictive value of oesophageal pH variables in children
with gastro-oesophageal reflux. Gut 1990;31:370–3.
Cucchiara 1996
Cucchiara S, Campanozzi A, Greco L, FrancoMT, Emiliano
M, Alfieri E, et al. Predictive value of esophageal manometry
and gastroesophageal pH monitoring for responsiveness
of reflux disease to medical therapy in children. American
Journal of Gastroeneterology 1996;91(4):680–5.
Davidson 2009
Davidson GP. Personal communication [Clarification of
trial characteristics and additional data]. Meeting 14.9.99.
Egger 1997
Egger M, Smith GD, Schneider M, Minder C. Bias in
meta-analysis detected by a simple, graphical test. BMJ
1997;315:629–34.
EMEA 2002
European Medicines Agency. Committee for proprietary
medicinal products (CPMP) opinion following and article
31 referral. Cisapride. EMEA/CPMP/24844/02. http:
//www.emea.europa.eu/pdfs/human/referral/cisapride/
2484402en.pdf London 7 October 2002. Accessed 26/01/
10.
Hampton 1990
Hampton FJ, MacFayden UM, Simpson H. Reproducibility
of 24 hour oesophageal pH studies in infants. Archives of
Diseases in Childhood 1990;65:1249–54.
Henney 2000
Henney JE. Withdrawal of troglitazone and cisapride.
JAMA 2000;283:2228.
Higgins 2009
Higgins JPT, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.0.2 [updated
September 2009]. The Cochrane Collaboration, 2009.
Available from www.cochrane–handbook.org.
Klausner 1998
Klausner MA. Jansen Pharmaceutical Research Foundation.
Important safety and efficacy information. http://
pharminfo.com/medwatch/mwrpt50.html (accessed June
2000) 1998.
Nelson 1997
Nelson SP, Chen EH, Syniar GM, Kaufer Christoffel K.
Prevalence of symptoms of gastroesophageal reflux during
infancy. Archives of Pediatrics and Adolescent Medicine 1997;
151:569–72.
Orenstein 2009
Orenstein SR. Personal communication [Additional data
and details regarding completion of the study]. Email
11.06.09.
12Cisapride treatment for gastro-oesophageal reflux in children (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rudolph 1996
Rudolph CD. Gastroesophageal Reflux. In: Rudolph AM,
Hoffman JIE, Rudolph CD editor(s). Rudolph’s Pediatrics.
Stamford, Connecticut: Appleton and Lange, 1996:
1058–60.
Schulz 1995
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical
evidence of bias. Dimensions of methodological quality
associated with estimates of treatment effects in controlled
trials. JAMA 1995;273:408–12.
Shulman 2000
Shulman RJ, Boyle JT, Colletti RB, Friedman R, Heyman
MB, Kearns G, et al. The North American Society for
Pediatrics Gastroenterology and Nutrition. An updated
medical position statement of the North American Society
for Pediatric Gastroenterology and Nutrition. Journal of
Pediatric Gastroenterology and Nutrition 2000;31(2):232–3.
Treem 1991
Treem WR, Davis PM, Hyams JS. Gastroesophageal reflux
in the older child: presentation, response to treatment
and long-term follow-up. Clinical Pediatrics 1991;30(7):
435–40.
Vandenplas 1993
Vandenplas Y, Ashkenazi A, Belli D, Boige N, Bouquet
J, Cadranel S, et al. A proposition for the diagnosis and
treatment of gastro-oesophageal reflux disease in children: a
report from a working group on gastro-oesophageal reflux
disease. European Journal of Pediatrics 1993;152:704–11.
Vandenplas 1999
Vandenplas Y, Belli DC, Benatar A. The role of cisapride in
the treatment of pediatric gastroesophageal reflux. Journal
of Pediatric Gastroenterology and Nutrition 1999;28:518–28.
Varty 1993
Varty K, Evans D, Kapila L. Paediatric gastro-oesophageal
reflux: prognostic indicators from pH monitoring. Gut
1993;34:1478–81.
Ward 1999
Ward RM, Lemons JA, Molteni RA. Cisapride: a survey
of the frequency of use and adverse events in premature
newborns. Pediatrics 1999;103:469–72.
References to other published versions of this review
Gilbert RE et al
Gilbert RE, Augood C, MacLennan S, Logan S. Cisapride
treatment for gastro-oesophageal reflux: a systematic review
of randomized controlled trials. Journal of Paediatrics and
Child Health 2000;36:525–9.
∗ Indicates the major publication for the study
13Cisapride treatment for gastro-oesophageal reflux in children (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cohen 1999
Methods Randomised, double-blind, placebo-controlled trial
Participants Age < 36 months
Clinical diagnosis ofGOR: frequentVorRoften associatedwith feedingdifficulties and/or excessive
crying.
Baseline 24-h oesophageal pH monitoring: RI ≥5% OR GOR score (Euler and Byrne) ≥50.
Exclusion criteria: anatomic abnormality of the GI tract, previous GI surgery, treatment with
anticholinergics, theophylline, other diagnosis which could explain vomiting
Interventions 2 weeks of either:
cisapride suspension (1mg/ml) 0.2 mg/kg qid (n=50*)
placebo (n=45*)
Outcomes Parental evaluation at 2 weeks:
overall symptom intensity on VAS 0-10 cm (0=absence of symptoms, 10= could not be worse)
improvement (marked=complete or near complete resolution of symptoms, moderate=partial res-
olution, minimal=slight improvement, unchanged, deterioration).
Evaluation during the 2 weeks of treatment:
presence of vomiting, gagging, crying (score 0-3).
AE: any, withdrawals due to AE.
Investigator assessment at 2 weeks:
24-h oesophageal pH
oesophagitis at biopsy.
Data (means, SD) also obtained for complications of GOR (apnoea, wheezing, nocturnal cough,
haematemesis) and weight gain (Davidson 2009).
Notes 68 participants (38, 30) completed the trial.
Withdrawn if: consent was withdrawn, serious AE, further investigations necessitated a change in
treatment.
A high proportion of participants had received prior treatment with: thickened feeds, positional
therapy, cisapride, H2 antagonists, antacids, metoclopramide, other
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Further details obtained from one of the trial
investigators (GD) by one of the review authors
(SM). Randomisation was centrally controlled
(outside of the three participating centres), by
computer generated code (Davidson 2009).
Allocation concealment? Low risk Adequate
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Cohen 1999 (Continued)
Blinding?
All outcomes
Unclear risk “matched placebo (both provided by Janssen Re-
search Foundation, Belgium)” p288. Further de-
tails not given
Cucchiara 1987
Methods Randomised, double-blind, placebo-controlled trial
Participants Age 75 days - 47 months
Reflux oesophagitis in all (endoscopy and biopsy).
Diagnosis of GOR made by oesophageal pH (pH<4 for ≥20min) and manometry.
Exclusion criteria: infections, neurologic, metabolic, renal disorders, abnormalities of the GI tract
Interventions 8 weeks of either:
cisapride syrup (1mg/ml) 0.3 mg/kg tid or
placebo syrup.
Outcomes Assessed at 8 weeks by investigator:
24-h pH
LOS pressure
oesophagitis at biopsy.
Improvement at end of treatment: cured (clinical, pH-metric and histological variables normalised)
, improved (at least one of the three variables had improved), unchanged, worsened
Notes 3 participants were withdrawn: 2 febrile URTI, 1 failed to take drug continuously.
Other outcomes measured: peristalsis amplitude, clinical score
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Details not given.
Allocation concealment? Unclear risk Unclear
Blinding?
All outcomes
Unclear risk “placebo syrup, which was identical to cisapride
in taste and appearance” p454. Further details
not given
Escobar Castro 1994
Methods Randomised, double-blind, placebo-controlled study
Participants Age 3 months - 5 yrs
V and R present
GOR at oesophageal pH monitoring (RI <3.5% considered normal).
No organic pathology to justify the reflux.
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Escobar Castro 1994 (Continued)
Interventions 4 weeks of either:
cisapride 0.2 mg/kg (n=15)
placebo (n=15).
Outcomes Assessment at 2 and 4 weeks (probably by parents) of digestive symptoms: severe (R and/or V after
each meal of an important part of the meal), moderate (R of a small quantity more than once a
day), mild (R of a very small quantity once a day or sometime during the week), absent.
Investigator assessment at 4 weeks: 24-h oesophageal pH, AE, complications
Notes 1 drop-out in the cisapride group (’lack of motivation’).
Other outcomesmeasured: radiological image, endoscopy, respiratory symptoms improvement (nil,
slight, good, excellent)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Details not given.
Allocation concealment? Unclear risk Unclear
Blinding?
All outcomes
Unclear risk Details not given.
Greally 1992
Methods Randomised study
Double-blind design was not feasible (see text for details).
Participants Age 2-18 months
Chronic vomiting and GOR confirmed by 24h pH oesophageal monitoring (pH<4 for ≥5% of
the recording period).
No neurological, respiratory, metabolic, GI disease, treatment with H2 antagonists, theophylline,
anticholinergic drugs
Interventions 4 weeks of either:
cisapride p.o. 0.2 mg/kg qid (n=26)
Gaviscon 1/2 sachet to each 90 ml feed qid (n=24, 21 also had Carobel)
Outcomes Parental evaluation at 4 weeks of improvement (improved, not improved).
Investigator evaluation at 4 weeks of 24-h pH (RE was defined as pH<4 for ≥15min)
Notes All 50 infants completed the study.
Other outcomes measured at 4 weeks: daily parental evaluation of severity of V: 0 (absent), 1(1-4
episodes/day), 2 (>4 episodes/day), leading to a final symptoms score (range 0-1); improvement in
diary scores
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Greally 1992 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Details not given.
Allocation concealment? Unclear risk Unclear
Blinding?
All outcomes
High risk Double-blind design was not feasible (see text of
review for details)
Levy 2001
Methods Randomised, double-blind, placebo-controlled study
Participants Age 6 months - 4 years (mean age 14.4 months)
Minimum 3 months of symptomatic GOR with failure to respond to at least 6 weeks of non-
surgical treatment other than cisapride
Interventions 3-8 weeks of either cisapride 0.6 mg/kg/day or placebo.
Outcomes Data on QTc retained in 4 (68 participants) of 7 study centres (134 participants in total) in the
trial. 19/68 excluded as ECGs recorded after 8 weeks of treatment. Mean QTc reported at 3-8
weeks of treatment and mean difference in QTc from baseline
Notes Data on symptoms of GOR not published “because efficacy results did not reach statistical signif-
icance”
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Details not given.
Allocation concealment? Unclear risk Unclear
Blinding?
All outcomes
Unclear risk “blindly assigned to receive either placebo or cis-
apride” p459. Further details not given
Moya 1999
Methods Randomised controlled trial, unblinded
Participants Age 1-4 months, total 26 infants
No previous illness, with frequent regurgitation (>5 regurgitations per day)
Exclusion criteria: receiving antireflux medication, breast fed
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Moya 1999 (Continued)
Interventions Two weeks of either:
no treatment~original formula (n= 6)
carob bean gum with formula (n=8)
corn syrup with formula (n=6)
cisapride with formula (n=6).
Outcomes Outcomes recorded by a daily diary by parents up to day 15
Mean daily number of regurgitations
Mean daily weight gain. No information on how daily means were calculated
Notes Cisapride dosage unclear - only noted as “usual dosage in 3 divided doses”
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Details not given.
Allocation concealment? Unclear risk Unclear
Blinding?
All outcomes
High risk Blinding not feasible, due to nature of different inter-
ventions (see above)
Orenstein 2000
Methods Multicentre, randomised controlled trial
Participants 96 children > 2 months old with biopsy-proven oesophagitis.
Interventions 1. cisapride 0.2 mg/kg qid and placebo
2. cimetidine 10 mg/kg qid and placebo
3. cisapride + cimetidine
4. placebo + placebo.
Outcomes Measured at 2, 6 and 12 months. Initial findings reported for 2 months.
1.Symptoms measured by parents using the Infant Gastroesophageal Reflux Questionnaire
2. Vomiting
3. Crying
4. Biopsy measuring histological parameters of papillary height and basal layer thickness
Notes Trial finished but only published as an abstract. Personal communication provided by Dr SR
Orenstein, Academic Hospital of Pittsburgh, USA (Orenstein 2009).
Cisapride versus no cisapride: symptom questionnaire showed 86% with cisapride were well or
better at 2 months compared with 70% for no cisapride groups (if 3 lost to follow up in cisapride
group and 8 given no cisapride were assumed to have worse symptoms).No significant improvement
in vomiting (frequency or volume). This paper was never published in article form as cisapride was
taken off the market in the US amid concerns about its toxicity. 100 infants were enrolled, and
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Orenstein 2000 (Continued)
nearly all of them completed the 12 months of the protocol, although follow up was discontinued
for the last few infants in concordance with the
wishes of the FDA and the company.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “randomised, double-blind in blocks of 8” pA20. Fur-
ther details not given
Allocation concealment? Unclear risk Unclear - details not given
Blinding?
All outcomes
Unclear risk “blindly assigned to 1 of 4 arms”, “At any visit with
both Sx & Bx unimproved, infants were rescued to
un-masked Cm-Cs, without un-masking prior Rx.”
P0791. Further details not given
Scott 1997
Methods Randomised, double-blind, placebo-controlled trial
Participants Age 6 weeks - 2 years
Daily R or V during a 1 week baseline period
AND ≥1 episode of GOR (pH<4 for >20min) at 18-h pH monitoring.
Exclusion criteria: not meeting the inclusion criteria, premature, previous GI surgery (excluding for
appendicitis), illnesses and drugs that could interfere with cisapride, reflux due to known anatomic
abnormalities, underlying disease, infection of the GI tract; parents who couldn’t express concern,
comply with study, complete diaries
Interventions 6 weeks of positioning and thickened feeds (where appropriate) and either:
cisapride suspension (1mg/ml) 0.2 mg/kg qid (n=23) or
placebo suspension (n=26).
Outcomes Assessed at 2, 4, 6 weeks by parent and investigator: global evaluation of condition on VAS 0-100
mm (0=the worst it’s ever been, 100=completely recovered); any AE, specific AE.
Assessed at 6weeks by parent and investigator: global evaluation of overall treatment (deterioration=
symptoms worse, poor=no improvement, fair=slight improvement, persistence of some symptoms,
good=improvement, occasional symptoms, excellent=complete relief of symptoms).
Assessed at 6 weeks by investigator: 24-h pH, LOS pressure, oesophagitis at biopsy
Notes 45 participants (21 cisapride, 24 placebo) were evaluated (4 were non-compliant or had violated
protocol).
Other outcomes: various at 24-h pH, swallow pressure, daily diary recording of each episode (none,
mild, moderate, severe), score for R and V
Risk of bias
19Cisapride treatment for gastro-oesophageal reflux in children (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Scott 1997 (Continued)
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “randomisation code for the allocation of pa-
tients to cisapride or placebo suspensionwas gen-
erated by computer” (p501)
Allocation concealment? Low risk Adequate
Blinding?
All outcomes
Unclear risk “matching suspension of placebo” p500. “The
double-blind code was to be broken only in the
event of an emergency.” p501. Further details
not given
Van Eygen 1989(a)
Methods Three trials:
I open trial (n=69)
II (Van Eygen 1989a) randomised, double-blind, placebo-controlled trial (n=23)
III (Van Eygen 1989b) dose-response trial (n=50).
Participants Age 5 days - 12 months
Excessive R or V at least twice a day in all children.
In trial II: GOR at radiology or pH monitoring in all children.
In trial III: GOR at radiology, endoscopy or pH monitoring in 16 children.
Non-pharmacologic measures (e.g. positioning, food thickening) had failed to improve the reflux
Interventions 4 weeks of either
Trial II: cisapride oral suspension 0.15 mg/kg tid (n=12)
placebo oral suspension (n=11).
Trial III: cisapride 0.1 mg/kg tid (n=14) (not used in the analysis)
cisapride 0.2 mg/kg tid (n=14)
placebo tid (n=17).
Outcomes Assessed at 2 and 4 weeks by the investigator: AE, global therapeutic result (poor=no change,
fair=distinct but slight improvement, good=marked reduction in R, excellent=virtually complete
symptomatic cure)
Notes In trial III: analysis based on 45 of 50 participants. There were 4 early drop-outs and 1 protocol
violation and a further 10 drop-outs (4 in the cisapride 0.2 mg/kg group and 6 in the placebo
group.
Other outcomes assessed at 2 and 4 weeks by investigator: severity of R (severe=the major part of
the meal is R, moderate=effortless R of a mouthful of feeding, slight=R of rather excessive saliva
only, no R); frequency of R (after each meal, at least twice a day, once a day or several times a week,
never)
Risk of bias
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Van Eygen 1989(a) (Continued)
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Details not given.
Allocation concealment? Unclear risk Unclear
Blinding?
All outcomes
Unclear risk “under double-blind conditions, the medica-
tions being identical in appearance and taste”
p670. Further details not given
Van Eygen 1989(b)
Methods Trial III referred to above. Please see above for details.
Participants
Interventions
Outcomes
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Details not given.
Allocation concealment? Unclear risk Unclear
Blinding?
All outcomes
Unclear risk “under double-blind conditions, the medica-
tions being identical in appearance and taste”
p670. Further details not given
Vandenplas 1991
Methods Randomised, double-blind, placebo-controlled trial
Participants Age 2 - 4 months
Pathological GOR of V and R for > 2 weeks, >6 times/day AND abnormal oesophageal pH
monitoring.
Exclusion criteria: reflux secondary to diseases (e.g. infections, allergy, pyloric stenosis)
Interventions 13-16 days of positional therapy and either:
cisapride (1 mg/ml) 0.2 mg/kg qid (n=21) or
placebo (n=21).
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Vandenplas 1991 (Continued)
Outcomes Parental evaluation of GOR severity at 2 weeks: 0 (no V at all), 1 (1-3 episodes of V or R/day), 2
(4-6 episodes of V or R/day), 3 (>6 episodes of V or R/day). NB: all had grade 3 at the beginning.
Investigator evaluation at 2 weeks: 24-h pH.
Notes None of the infants received milk-thickening products.
29 completed the study, 13 exclusions post-randomisation: unexpectedweaning (3,3), withdrawal of
permission for second pHmonitoring because symptoms had improved (4,1), lack of improvement
and parents refused to continue (0,2)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Details not given.
Allocation concealment? Unclear risk Unclear
Blinding?
All outcomes
Unclear risk “Both products (cisapride, 1mg/
ml, and placebo) were prepared in the same way
and could not be recognised by taste or aspect.”
p45. “The randomisation code was broken after
the second pH monitoring” p45. Further details
not given
* Number of participants in brackets represents number randomised to respective treatment group.
AE = adverse events, GI = gastrointestinal, GOR = gastro-oesophageal reflux, LOS = lower oesophageal sphincter, R = regurgitation,
RE = reflux episode, RI = reflux index (percentage of time in 24 h during which pH < 4), URTI = upper respiratory tract infection, V
= vomiting, VAS = visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Barnett 2001 Study participants were preterm neonates.
Cucchiara 1990 Cisapride given intravenously in a single dose over 5 minutes. No mention of study being randomised
Enriquez 1998 Cisapride was administered prophylactically during the introduction of enteral feeding by nasogastric tube to
preterm infants of less than 33 weeks gestation at birth
Heine 1996 The outcomes reported by this study (i.e. drooling) are not relevant to the review
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(Continued)
McClure 1999 The outcomes reported in this study (i.e. half gastric emptying time, whole gastrointestinal transit time) are not
relevant to the review. Cisapride was prescribed for clinically diagnosed gastro-oesophageal reflux or poor feed
tolerance in very preterm infants (less than 32 weeks of gestation)
Pezzati 2001 Study participants were preterm neonates less than 34 weeks gestation. Cisapride was administered for feed
intolerance by naso-gastric tube
Reddy 2000 Preterm neonates less than 34 weeks gestation. Cisapride administered prophylactically during the introduction
of enteral feeding
Saye 1987 All infants and children were suspected of having GOR (only 5 of them had digestive symptoms) and cisapride
treatment was given for only 16 hours
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D A T A A N D A N A L Y S E S
Comparison 1. Main analysis for cisapride versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ’Worse, same or slight
improvement’ versus ’moderate
or excellent improvement’
7 236 Odds Ratio (M-H, Random, 95% CI) 0.34 [0.10, 1.19]
2 Mean daily regurgitations 1 12 Mean Difference (IV, Fixed, 95% CI) -0.90 [-4.10, 2.30]
3 Mean daily weight gain 1 12 Mean Difference (IV, Fixed, 95% CI) -0.30 [-7.65, 7.05]
4 Reflux index 5 176 Mean Difference (IV, Random, 95% CI) -6.49 [-10.13, -2.85]
5 Adverse events 4 190 Odds Ratio (M-H, Random, 95% CI) 1.86 [0.88, 3.93]
Comparison 2. Main analysis for cisapride versus Gaviscon
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ’Worse, same or slight
improvement’ versus ’moderate
or excellent improvement’
1 50 Odds Ratio (M-H, Random, 95% CI) 3.26 [0.93, 11.38]
Comparison 3. Main analysis for cisapride versus dietary interventions
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ’Worse, same or slight
improvement’ versus ’moderate
or excellent improvement’
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Carob bean: mean daily
regurgitations
1 12 Mean Difference (IV, Fixed, 95% CI) 0.30 [-2.71, 3.31]
3 Carob bean: mean daily weight
gain
1 12 Mean Difference (IV, Fixed, 95% CI) 2.60 [-2.12, 7.32]
4 Corn syrup: mean daily
regurgitations
1 14 Mean Difference (IV, Fixed, 95% CI) -0.30 [-3.11, 2.51]
5 Corn syrup: mean daily weight
gain
1 14 Mean Difference (IV, Fixed, 95% CI) -3.70 [-10.46, 3.06]
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Comparison 4. Sensitivity analyses for cisapride versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Best case scenario 8 302 Odds Ratio (M-H, Random, 95% CI) 0.21 [0.08, 0.54]
2 Worst case scenario 7 290 Odds Ratio (M-H, Random, 95% CI) 0.70 [0.18, 2.65]
3 Change in outcome definition:
’any symptoms’ vs ’no
symptoms’ at end of treatment
6 168 Odds Ratio (M-H, Random, 95% CI) 0.19 [0.08, 0.44]
Analysis 1.1. Comparison 1 Main analysis for cisapride versus no treatment, Outcome 1 ’Worse, same or
slight improvement’ versus ’moderate or excellent improvement’.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 1 Main analysis for cisapride versus no treatment
Outcome: 1 ’Worse, same or slight improvement’ versus ’moderate or excellent improvement’
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Scott 1997 10/20 7/16 16.5 % 1.29 [ 0.34, 4.82 ]
Cucchiara 1987 2/8 7/9 12.2 % 0.10 [ 0.01, 0.90 ]
Van Eygen 1989(b) 2/10 7/11 13.4 % 0.14 [ 0.02, 1.03 ]
Van Eygen 1989(a) 2/12 3/11 13.2 % 0.53 [ 0.07, 4.01 ]
Vandenplas 1991 7/21 11/21 16.9 % 0.45 [ 0.13, 1.58 ]
Escobar Castro 1994 1/14 14/15 9.7 % 0.01 [ 0.00, 0.10 ]
Cohen 1999 27/38 15/30 18.0 % 2.45 [ 0.90, 6.68 ]
Total (95% CI) 123 113 100.0 % 0.34 [ 0.10, 1.19 ]
Total events: 51 (Treatment), 64 (Control)
Heterogeneity: Tau2 = 1.97; Chi2 = 24.23, df = 6 (P = 0.00047); I2 =75%
Test for overall effect: Z = 1.69 (P = 0.092)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.2. Comparison 1 Main analysis for cisapride versus no treatment, Outcome 2 Mean daily
regurgitations.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 1 Main analysis for cisapride versus no treatment
Outcome: 2 Mean daily regurgitations
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Moya 1999 6 -7 (3.4) 6 -6.1 (2.1) 100.0 % -0.90 [ -4.10, 2.30 ]
Total (95% CI) 6 6 100.0 % -0.90 [ -4.10, 2.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
Analysis 1.3. Comparison 1 Main analysis for cisapride versus no treatment, Outcome 3 Mean daily weight
gain.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 1 Main analysis for cisapride versus no treatment
Outcome: 3 Mean daily weight gain
Study or subgroup Favours experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Moya 1999 6 6.6 (5.7) 6 6.9 (7.2) 100.0 % -0.30 [ -7.65, 7.05 ]
Total (95% CI) 6 6 100.0 % -0.30 [ -7.65, 7.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
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Analysis 1.4. Comparison 1 Main analysis for cisapride versus no treatment, Outcome 4 Reflux index.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 1 Main analysis for cisapride versus no treatment
Outcome: 4 Reflux index
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cohen 1999 38 7.1 (7.9) 30 10 (7.8) 35.3 % -2.90 [ -6.65, 0.85 ]
Vandenplas 1991 14 12.5 (8.61) 15 18.5 (11.62) 16.9 % -6.00 [ -13.41, 1.41 ]
Escobar Castro 1994 14 3.83 (3.47) 15 13.42 (7.47) 32.3 % -9.59 [ -13.78, -5.40 ]
Scott 1997 18 15 (20) 15 20 (17) 7.2 % -5.00 [ -17.62, 7.62 ]
Cucchiara 1987 8 11.83 (11.07) 9 23.85 (13.57) 8.2 % -12.02 [ -23.74, -0.30 ]
Total (95% CI) 92 84 100.0 % -6.49 [ -10.13, -2.85 ]
Heterogeneity: Tau2 = 6.09; Chi2 = 6.46, df = 4 (P = 0.17); I2 =38%
Test for overall effect: Z = 3.49 (P = 0.00047)
-10 -5 0 5 10
Favours treatment Favours control
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Analysis 1.5. Comparison 1 Main analysis for cisapride versus no treatment, Outcome 5 Adverse events.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 1 Main analysis for cisapride versus no treatment
Outcome: 5 Adverse events
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cohen 1999 42/50 32/45 56.7 % 2.13 [ 0.79, 5.76 ]
Escobar Castro 1994 0/14 0/15 Not estimable
Scott 1997 14/23 13/26 43.3 % 1.56 [ 0.50, 4.85 ]
Cucchiara 1987 0/8 0/9 Not estimable
Total (95% CI) 95 95 100.0 % 1.86 [ 0.88, 3.93 ]
Total events: 56 (Treatment), 45 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 2.1. Comparison 2 Main analysis for cisapride versus Gaviscon, Outcome 1 ’Worse, same or slight
improvement’ versus ’moderate or excellent improvement’.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 2 Main analysis for cisapride versus Gaviscon
Outcome: 1 ’Worse, same or slight improvement’ versus ’moderate or excellent improvement’
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Greally 1992 12/26 5/24 100.0 % 3.26 [ 0.93, 11.38 ]
Total (95% CI) 26 24 100.0 % 3.26 [ 0.93, 11.38 ]
Total events: 12 (Treatment), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.064)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 3.2. Comparison 3 Main analysis for cisapride versus dietary interventions, Outcome 2 Carob
bean: mean daily regurgitations.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 3 Main analysis for cisapride versus dietary interventions
Outcome: 2 Carob bean: mean daily regurgitations
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Moya 1999 6 -7 (3.4) 6 -7.3 (1.6) 100.0 % 0.30 [ -2.71, 3.31 ]
Total (95% CI) 6 6 100.0 % 0.30 [ -2.71, 3.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
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Analysis 3.3. Comparison 3 Main analysis for cisapride versus dietary interventions, Outcome 3 Carob
bean: mean daily weight gain.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 3 Main analysis for cisapride versus dietary interventions
Outcome: 3 Carob bean: mean daily weight gain
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Moya 1999 6 6.6 (5.7) 6 4 (1.5) 100.0 % 2.60 [ -2.12, 7.32 ]
Total (95% CI) 6 6 100.0 % 2.60 [ -2.12, 7.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
Analysis 3.4. Comparison 3 Main analysis for cisapride versus dietary interventions, Outcome 4 Corn syrup:
mean daily regurgitations.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 3 Main analysis for cisapride versus dietary interventions
Outcome: 4 Corn syrup: mean daily regurgitations
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Moya 1999 6 -7 (3.4) 8 -6.7 (1) 100.0 % -0.30 [ -3.11, 2.51 ]
Total (95% CI) 6 8 100.0 % -0.30 [ -3.11, 2.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
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Analysis 3.5. Comparison 3 Main analysis for cisapride versus dietary interventions, Outcome 5 Corn syrup:
mean daily weight gain.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 3 Main analysis for cisapride versus dietary interventions
Outcome: 5 Corn syrup: mean daily weight gain
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Moya 1999 6 6.6 (5.7) 8 10.3 (7.2) 100.0 % -3.70 [ -10.46, 3.06 ]
Total (95% CI) 6 8 100.0 % -3.70 [ -10.46, 3.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
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Analysis 4.1. Comparison 4 Sensitivity analyses for cisapride versus no treatment, Outcome 1 Best case
scenario.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 4 Sensitivity analyses for cisapride versus no treatment
Outcome: 1 Best case scenario
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cohen 1999 27/50 30/45 20.8 % 0.59 [ 0.26, 1.35 ]
Cucchiara 1987 2/10 8/10 10.9 % 0.06 [ 0.01, 0.56 ]
Escobar Castro 1994 1/15 14/15 7.8 % 0.01 [ 0.00, 0.09 ]
Moya 1999 6/6 6/6 Not estimable
Scott 1997 10/23 17/26 18.2 % 0.41 [ 0.13, 1.29 ]
Van Eygen 1989(a) 2/12 3/11 11.9 % 0.53 [ 0.07, 4.01 ]
Van Eygen 1989(b) 2/14 13/17 12.9 % 0.05 [ 0.01, 0.33 ]
Vandenplas 1991 7/21 11/21 17.5 % 0.45 [ 0.13, 1.58 ]
Total (95% CI) 151 151 100.0 % 0.21 [ 0.08, 0.54 ]
Total events: 57 (Treatment), 102 (Control)
Heterogeneity: Tau2 = 1.00; Chi2 = 16.80, df = 6 (P = 0.01); I2 =64%
Test for overall effect: Z = 3.20 (P = 0.0014)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 4.2. Comparison 4 Sensitivity analyses for cisapride versus no treatment, Outcome 2 Worst case
scenario.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 4 Sensitivity analyses for cisapride versus no treatment
Outcome: 2 Worst case scenario
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cohen 1999 39/50 15/45 16.6 % 7.09 [ 2.85, 17.65 ]
Cucchiara 1987 4/10 7/10 13.4 % 0.29 [ 0.04, 1.82 ]
Escobar Castro 1994 2/15 14/15 11.0 % 0.01 [ 0.00, 0.14 ]
Scott 1997 12/23 7/26 15.8 % 2.96 [ 0.90, 9.75 ]
Van Eygen 1989(a) 2/12 3/11 12.8 % 0.53 [ 0.07, 4.01 ]
Van Eygen 1989(b) 6/14 7/17 14.9 % 1.07 [ 0.26, 4.49 ]
Vandenplas 1991 7/21 11/21 15.6 % 0.45 [ 0.13, 1.58 ]
Total (95% CI) 145 145 100.0 % 0.70 [ 0.18, 2.65 ]
Total events: 72 (Treatment), 64 (Control)
Heterogeneity: Tau2 = 2.56; Chi2 = 35.41, df = 6 (P<0.00001); I2 =83%
Test for overall effect: Z = 0.53 (P = 0.60)
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Analysis 4.3. Comparison 4 Sensitivity analyses for cisapride versus no treatment, Outcome 3 Change in
outcome definition: ’any symptoms’ vs ’no symptoms’ at end of treatment.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 4 Sensitivity analyses for cisapride versus no treatment
Outcome: 3 Change in outcome definition: ’any symptoms’ vs ’no symptoms’ at end of treatment
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cucchiara 1987 4/8 8/9 11.4 % 0.13 [ 0.01, 1.52 ]
Escobar Castro 1994 7/14 14/15 13.7 % 0.07 [ 0.01, 0.70 ]
Moya 1999 6/6 6/6 Not estimable
Van Eygen 1989(a) 4/12 10/11 12.6 % 0.05 [ 0.00, 0.54 ]
Van Eygen 1989(b) 14/28 14/17 33.9 % 0.21 [ 0.05, 0.91 ]
Vandenplas 1991 16/21 18/21 28.5 % 0.53 [ 0.11, 2.59 ]
Total (95% CI) 89 79 100.0 % 0.19 [ 0.08, 0.44 ]
Total events: 51 (Treatment), 70 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.69, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.89 (P = 0.00010)
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. randomised controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. humans.sh.
11. 9 and 10
12. exp esophageal motility disorders/
13. exp esophagitis/
14. esophagitis.tw.
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15. oesophagitis.tw.
16. exp gastroesophageal reflux/
17. (gastro?esophageal adj5 reflux).tw.
18. (gastro esophageal adj5 reflux).tw.
19. (gastro oesophageal adj5 reflux).tw.
20. infantile reflux.tw.
21. regurgitat$.tw.
22. GORD.tw.
23. GERD.tw.
24. GER.tw.
25. exp proton pump inhibitors/
26. (proton adj3 pump adj3 inhibitor$).tw.
27. PPI$.tw.
28. exp omeprazole/
29. omeprazole.tw.
30. (lansoprazole or lanzoprazole).tw.
31. pantoprazole.tw.
32. rabeprazole.tw.
33. exp Histamine h2 antagonists/
34. h2 receptor antagonist$.tw.
35. exp cimetidine/
36. exp ranitidine/
37. exp famotidine/
38. exp nizatidine/
39. cimetidine.tw.
40. ranitidine.tw.
41. famotidine.tw.
42. nizatidine.tw.
43. (prokinetic or prokinetics).tw.
44. metoclopramide.tw.
45. exp metoclopramide/
46. domperidone.tw.
47. exp domperidone/
48. bethanechol.tw.
49. exp bethanechol/
50. exp cisapride/
51. cisapride.tw.
52. (Acenalin or Alimix or Arcasin or Cisaprid or Prepulsid or Propulsid or Propulsin or Propulsit or R 51 619 or R 51,619 or R 51619
or R51619 or Risamol).tw.
53. or/12-24
54. or/25-49
55. 53 or 54
56. or/50-52
57. 55 and 56
58. exp infant, newborn/
59. exp infant/
60. exp child/
61. exp adolescent/
62. infan$.tw.
63. child$.tw.
64. neonat$.tw.
65. newborn$.tw.
66. pediatric$.tw.
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67. paediatric$.tw.
68. juvenile$.tw.
69. (young adj3 people).tw.
70. youth$.tw.
71. adolescen$.tw.
72. or/58-71
73. 57 and 72
74. 11 and 73
75. limit 74 to yr=“2005-2009”
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Last assessed as up-to-date: 4 November 2009.
Date Event Description
12 October 2010 Review declared as stable Review no longer being updated due to stability of evidence.
H I S T O R Y
Protocol first published: Issue 1, 2000
Review first published: Issue 3, 2003
Date Event Description
26 May 2010 Amended Plain language summary revised
2 March 2010 New search has been performed Updated, one new study included, conclusions not
changed.
5 February 2010 New citation required but conclusions have not
changed
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13 June 2006 New search has been performed Minor update new studies sought but none found
5 April 2002 New search has been performed New studies found and included or excluded
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